Literature DB >> 28857845

Epilepsy and osteoporosis risk.

Philip M Dussault1, Antonio A Lazzari.   

Abstract

PURPOSE OF REVIEW: It is well-recognized that individuals with epilepsy have an increased risk of vertebral and nonvertebral fractures; this increased risk has been described to be secondary to an increased bone fragility and to an increased risk of falls. Osteoporosis is the most common bone disease which has been characterized by microarchitectural deterioration of trabecula and cortical bone mass with a decrease in bone mineral density and bone strength. Specific side effects of antiepileptic drugs (AEDs) on bone metabolism have been identified; recent research publications further characterized some of the specific side effects of AEDs on bone metabolism. It is the purpose of this review to describe recent advances on the knowledge of the effects of AEDs on bone metabolism and the cause of osteoporosis in the field of epilepsy. RECENT
FINDINGS: Recent literature demonstrates that the increased risk of fractures in the epileptic patient population is likely multifactorial and includes seizure activity, injuries from falls, decreased bone strength, adverse effects from AEDs. Reviewed publications suggest that the mechanism of adverse effects on bone metabolism may differ among different AEDs. The impact of vitamin D deficiency or its metabolism in the epileptic population has also been a concern of several reviewed publications.
SUMMARY: This is a review is of the recent epilepsy and osteoporosis literature published over the past 18 months, highlighting reports and studies concerning the cause, pathogenesis, and possible preventive measures and effects of AEDs on changes of bone metabolism, bone loss, and development of osteoporosis. In addition, we also reviewed articles focusing on issues of prevention and treatment of osteoporosis in individuals with epilepsy. We utilized the search engines of PubMed and Cochrane Reviews from January 2016 to June 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28857845     DOI: 10.1097/MED.0000000000000366

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  7 in total

1.  [Pain and epilepsy : A clinical, neuroanatomical and pathophysiological review].

Authors:  P Martin
Journal:  Schmerz       Date:  2018-08       Impact factor: 1.107

2.  High prevalence of vertebral fractures in seizure patients with normal bone density receiving chronic anti-epileptic drugs.

Authors:  P M Dussault; D McCarthy; S A Davis; M Thakore-James; A A Lazzari
Journal:  Osteoporos Int       Date:  2021-04-06       Impact factor: 4.507

3.  Effect of alendronate on the femoral metaphyseal defect under carbamazepine in ovariectomized rats.

Authors:  Ruotian Zhang; Min Yang; Yang Li; Hedong Liu; Maoxian Ren; Zhou-Shan Tao
Journal:  J Orthop Surg Res       Date:  2021-01-06       Impact factor: 2.359

4.  Anticonvulsant use and bone health in a population-based study of men and women: cross-sectional data from the Geelong Osteoporosis Study.

Authors:  Vinoomika Chandrasekaran; Julie A Pasco; Amanda L Stuart; Sharon L Brennan-Olsen; Michael Berk; Jason M Hodge; Rasika M Samarasinghe; Lana J Williams
Journal:  BMC Musculoskelet Disord       Date:  2021-02-11       Impact factor: 2.362

5.  Anticonvulsant use and fracture: a case-control study.

Authors:  Vinoomika Chandrasekaran; Amanda L Stuart; Julie A Pasco; Sharon L Brennan-Olsen; Michael Berk; Jason M Hodge; Rasika M Samarasinghe; Lana J Williams
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-09-01       Impact factor: 2.041

6.  [Medicine for people with disabilities : Special features of trauma surgical care of extremity injuries in people with severe mental and physical disabilities].

Authors:  Niklas Grüneweller; Dirk Wähnert; Nathalie Schillians; Adrian Komadinic; Thomas Vordemvenne
Journal:  Unfallchirurg       Date:  2021-11-09       Impact factor: 1.000

Review 7.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.